Trial Profile
Study of Changes in CD4 Lymphocyte Count in Patients With a HAART Regimen Including DDI [didanosine] + Tenofovir [disoproxil fumarate] and With Viral Suppression Following the Replacement of Tenofovir With Abacavir Once Daily or Following the Double Replacement of DDI + Tenofovir With Abacavir + Lamivudine in a Single Tablet
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Abacavir (Primary) ; Lamivudine/abacavir (Primary) ; Didanosine
- Indications HIV-1 infections
- Focus Therapeutic Use
- 05 Jun 2007 Status change from in progress to completed.
- 08 Oct 2006 New trial record.